Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	18	Ruvkun NEAR Gary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/04 13:21
L2	827	PTEN	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/04 13:22
L3	15	daf-18	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/04 13:22
L4	453	L2 and (obesity glucose)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/04 13:22
L5	111	lipid phosphatase	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/10/04 13:23
L6	66	L2 and L5	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/10/04 13:23
L7	24	L5 and obesity	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/10/04 13:24
L8	3	pten lipid phosphatase obesity	US-PGPUB; USPAT; EPO; JPO; DERWENT	SAME	ON	2005/10/04 13:24
L9	4	pten lipid phosphatase glucose	US-PGPUB; USPAT; EPO; JPO; DERWENT	SAME	ON	2005/10/04 13:24
L10	3	pten phosphatase obesity	US-PGPUB; USPAT; EPO; JPO; DERWENT	SAME	ON .	2005/10/04 13:25
L11	64	pten phosphatase and obesity	US-PGPUB; USPAT; EPO; JPO; DERWENT	SAME	ON	2005/10/04 13:25
L12	6	ogg scott	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/10/04 13:25
L13	4	I12 and I2	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/10/04 13:26

L14	6	l12 and l1	US-PGPUB;	NEAR	ON	2005/10/04 13:26
			USPAT;			
			EPO; JPO;			
			DERWENT			

L8

L9

TI

SO

AB

PΙ

US 2001029617

BY, KG, KZ, MD, RU, TJ, TM

(FILE 'HOME' ENTERED AT 13:28:10 ON 04 OCT 2005) FILE 'MEDLINE, CANCERLIT, AGRICOLA, CAPLUS, SCISEARCH' ENTERED AT 13:28:18 ON 04 OCT 2005 L1 7018 S PTEN L2 774 S LIPID PHOSPHATASE L3180319 S OBESITY L414460 S IMPAIRED GLUCOSE L5 0 S L1 (L) L2 (L) L3 (L) L4 L6 447 S L1 (L) L2 L7 0 S L6 (L) L3 1 S L6 (L) L4 E RUVKUN GARY?/AU E RUVKUN G?/AU 176 S E1 E OGG S?/AU L1011 S E4 L11187 S L9 OR L10 5 S L11 AND L1 L12L132 DUP REM L12 (3 DUPLICATES REMOVED) L1435 S L1 AND L3 L15 25 DUP REM L14 (10 DUPLICATES REMOVED) L16 1 S L1 AND L4 L17 0 S L15 AND PY<=1997 => d an ti so au ab pi 116 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN AN2000:384548 CAPLUS DN 133:39116 Genes and polypeptides involved in insulin signaling pathways for glucose tolerance, obesity, and longevity and their uses as therapeutic and diagnostic tools PCT Int. Appl., 402 pp. CODEN: PIXXD2 Ruvkun, Gary; Ogg, Scott IN Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compns. for identifying or treating such conditions. The Caenorhabditis elegans metabolic regulatory genes daf-2 and age-1 encode homologs of the mammalian insulin receptor/phosphoinositol 3-kinase signaling pathway proteins, resp. Also, the C. elegans PKB kinase and AKT kinase act downstream of these genes, as their mammalian homologs act downstream of insulin signaling. The C. elegans PTEN lipid phosphatase homolog, DAF-18, acts upstream of AKT in this signaling pathway. Further, the DAF-16 forkhead protein represents the major transcriptional output of this insulin signaling pathway. Addnl. evidence indicates that the DAF-16, DAF-3, DAF-8, and DAF-14 transcriptional outputs of converging signaling pathways regulate metabolism The congruence between the C. elegans and mammalian insulin signaling pathways strongly supports the contention that new genes identified in the C. elegans pathway also act in mammalian insulin signaling. Exemplary sequences and functional characteristics of the C. elegans daf genes and their human homologs are provided. PATENT NO. KIND DATE APPLICATION NO. \_ \_ \_ \_ -----WO 2000033068 20000608 WO 1999-US28529 A1 19991202 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RÚ, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,

19981203

A1 20011011 US 1998-205658

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6861256 B2 20050301

AU 2000017496 A5 20000619 AU 2000-17496 19991202 EP 1163515 A1 20011219 EP 1999-960641 19991202

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO

L6 ANSWER 2 OF 9 MEDLINE on STN

DUPLICATE 2

- AN 2004545479 MEDLINE
- TI Enhanced insulin sensitivity, energy expenditure and thermogenesis in adipose-specific Pten suppression in mice.
- SO Nature medicine, (2004 Nov) 10 (11) 1208-15. Electronic Publication: 2004-10-17.
  - Journal code: 9502015. ISSN: 1078-8956.
- AU Komazawa Nobuyasu; Matsuda Morihiro; Kondoh Gen; Mizunoya Wataru; Iwaki Masanori; Takagi Toshiyuki; Sumikawa Yasuyuki; Inoue Kazuo; Suzuki Akira; Mak Tak Wah; Nakano Toru; Fushiki Tohru; Takeda Junji; Shimomura Iichiro
- Pten is an important phosphatase, suppressing the ABphosphatidylinositol-3 kinase/Akt pathway. Here, we generated adipose-specific Pten-deficient (AdipoPten-KO) mice, using newly generated Acdc promoter-driven Cre transgenic mice. AdipoPten-KO mice showed lower body and adipose tissue weights despite hyperphagia and enhanced insulin sensitivity with induced phosphorylation of Akt in adipose tissue. AdipoPten-KO mice also showed marked hyperthermia and increased energy expenditure with induced mitochondriagenesis in adipose tissue, associated with marked reduction of p53, inactivation of Rb, phosphorylation of cyclic AMP response element binding protein (CREB) and increased expression of Ppargcla, the gene that encodes peroxisome proliferative activated receptor gamma coactivator 1 alpha. Physiologically, adipose Pten mRNA decreased with exposure to cold and increased with obesity, which were linked to the mRNA alterations of mitochondriagenesis. Our results suggest that altered expression of adipose Pten could regulate insulin sensitivity and energy expenditure. Suppression of adipose Pten may become a beneficial strategy to treat type 2 diabetes and obesity.